Background: Matriptase and prostasin form a proteolytic pathway in which the hierarchical placement of the two proteases is unclear. Results: Prostasin stimulates matriptase activation non-enzymatically. Matriptase zymogen can activate prostasin. Conclusion: Matriptase and prostasin form a reciprocal zymogen activation complex with unique features. Significance: A general model for activation of the two membrane-anchored serine proteases is proposed.
zymogen to autoactivate and the ability of a fulllength soluble matriptase ectodomain zymogen to hydrolyze small model substrates and to incorporate activity-dependent small molecule probes into its active site (14, 15) .
Prostasin is synthesized as an approximately 40 kDa inactive glycophosphoinositol (GPI)-anchored trypsin-like serine protease zymogen that is activated by a single proteolytic cleavage after Arg 44 within the amino acid sequence QPR 44 -ITG (amino acid numbering including the prostasin signal peptide). The prostasin zymogen has been reported to be devoid of enzymatic activity and does not autoactivate in cell-based or in purified biochemical systems, consistent with the inability of prostasin to cleave model peptides resembling its own activation cleavage site (16) (17) (18) .
The activity of matriptase and prostasin is tightly regulated by the Kunitz-type transmembrane serine protease inhibitors, hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2, and, likely, by other serine protease inhibitors, including members of the serpin family (19) (20) (21) (22) (23) (24) (25) (26) .
Multiple studies have converged to show that matriptase and prostasin, under physiological conditions, form part of a single proteolytic pathway on the surface of epithelial cells (2, (25) (26) (27) (28) (29) . Considerable uncertainty exists, however, as to the specific interrelationship between the two proteases. Matriptase was originally proposed to autoactivate and subsequently activate prostasin, based on the capacity of recombinant soluble matriptase to autoactivate, the inability of recombinant soluble prostasin zymogen to do so, and the efficient activation of soluble prostasin zymogen by soluble activated matriptase (27, 30) . This hypothesis, however, proved incompatible with recent genetic and cell-based studies that conclusively demonstrated that prostasin is required for matriptase activation in the context of development and the homeostasis of simple epithelia (25, 28, 29) . Adding further complexity, although prostasin is absolutely required for matriptase activation in several in vivo and cellbased contexts, a recent study using purified soluble versions of each protease reported that prostasin is unable to directly activate matriptase, even at very high enzyme to substrate ratios (29) . However, the potential role of membrane-anchorage of the two proteases on matriptase activation by prostasin was not accounted for.
In this study, we have investigated the mechanistic relationship between matriptase and prostasin in a reconstituted cell-based system, employing epithelial cells with low endogenous expression of either protease and a battery of matriptase and prostasin mutants. We show that matriptase and prostasin form a reciprocal zymogen activation complex in which matriptase activation is induced by prostasin. Uniquely, however, prostasin can induce matriptase activation independent of prostasin zymogen conversion or prostasin catalytic activity. Conversely, prostasin activation is matriptase dependent, but prostasin activation by matriptase can be mediated by the matriptase zymogen. Consistent with these findings, transgenic mice with epidermal overexpression of prostasin mutants that are either activation site cleavageresistant or catalytically-inactive displayed phenotypes that were indistinguishable from transgenic mice overexpressing wildtype prostasin. Our proposed model for prostasininduced allosteric activation of matriptase and matriptase zymogen activation of prostasin provides a tentative explanation for several previously reported unresolved observations.
EXPERIMENTAL PROCEDURES
Cell Culture-HEK293 cells were grown in Dulbecco's Modified Eagle Medium supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 100 units/ml penicillin and 100 ȝg/ml streptomycin (Gibco Life Technologies), Grand Island, NY) at 37qC in an atmosphere of 5% CO 2 . Cells were seeded onto six-well plates pre-coated with poly-lysine and used for transfection experiments at 95% confluency the following day. Caco-2 cells were grown and induced to form monolayers as described previously (31) . DNA constructs-The mammalian expression vector pcDNA3.1, containing a full-length human matriptase cDNA (12) , was used for generation of the matriptase activation site variants R614A, Q, E and enteropeptidase (EP, T610RQAR614 to D610DDDK614), and the matriptase active site mutant S805A using the QuickChange kit from Stratagene (Stratagene, La Jolla, CA) according to the manufacturer's instructions. The mammalian expression vector pIRES2-EGFP containing a fulllength human prostasin cDNA (27) was used for the generation of the prostasin active site mutant S238A using the QuickChange kit from Stratagene. To generate the prostasin activation cleavage site mutant R44Q, a 569 bp EcoRIEcoNI fragment of the human prostasin cDNA was replaced with a synthetic DNA fragment (Blue Heron, Bothell, WA) containing a two nucleotide change from CGC, encoding R44, to CAA encoding Q44. pcDNA3.1 containing fulllength human HAI-1 cDNA has been described previously (12) . For generation of the human HAI-1-FLAG expression plasmid, the FLAG-tag was inserted between amino acids 38 and 39 to preserve the N-terminal signal peptide (amino acids . The pcDNA3.1 vector containing fulllength human HAI-1 cDNA (inserted with EcoRI) was BamHI digested, removing a 585 base pair fragment. A DNA sequence was designed to be identical to the BamHI-excised HAI-1 fragment, but with the addition of a FLAG-tag positioned as described above, was ordered from Blue Heron and inserted into the BamHI sites of the vector. Transient transfection of HEK293 cells HEK293 cells were plated using 10 6 cells per well in six-well plates and transfected at 95% confluency using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA), according to the protocol supplied by the manufacturer, using a total of 4 μg of DNA and 10 μl of transfection agent. For all co-transfections, the same total quantity of DNA was introduced by including empty pcDNA3.1 vector. The transfection medium was changed to growth medium 12-24 hours posttransfection. Cell extracts of transiently transfected cells were obtained 48 h post-transfection using ice-cold lysis buffer (PBS containing 1% Triton X-100, 0.5% sodium deoxycholate and protease inhibitors (Sigma, St. Louis, MO). The cells were removed from the plate by using 250 μl lysis buffer per well and the lysates were centrifuged at 20,000 x g for 15 min at 4°C to pellet insoluble material. The supernatant was transferred to new Eppendorf tubes. Matriptase knock down in Caco-2 cells using shRNA-Sub-confluent Caco-2 cells (10 6 cells per transfection) were transfected with shRNA (matriptase, 1:1:1 mix of ST14HSS186126, 186125, 11026 or control shRNA, 46-2001, Invitrogen) in suspension using Dharmafect1 (Thermo Scientific, Hudson, NH) following the manufacturer's instructions using 3.3 μl of 20 μM RNA stock and 7 μl transfection agent in a final volume of 2 ml serum-free medium. The medium was changed 12-24 h after transfection and 72 h post-transfection the cells were harvested in lysis buffer as described above for the HEK293 cells. ImmunoprecipitationMatriptase-Transiently-transfected HEK293 cells in six-well plates were harvested in 250 μl lysis buffer as described above. The supernatant was divided with 50 μl being used for the analysis of the protein expression before immunoprecipitation and the remaining 200 μl being used for the matriptase immunoprecipitation. GammaBind G Sepharose (GE Healthcare, Piscataway, NJ) was prepared according to manufacturer's instructions and the 200 Pl supernatants were increased with an extra 300 μl lysis buffer to give a final volume of 500 μl. The supernatants were pre-cleared with 30 μl Sepharose/sample for 30 min at 4°C with end-over-end rotation. After pre-clearing, the samples were centrifuged at 5000 x g for 1 min at 4°C, and each supernatant was transferred to a new Eppendorf tube containing 70 μl G Sepharose plus 4.5 μg sheep anti-human matriptase antibody (R&D, AF3946, Minneapolis, MN). Samples were incubated for 3 h at 4°C with end-over-end rotation. After incubation, the samples were centrifuged for 30 s at 5000 x g at 4°C to precipitate the G Sepharose and the supernatant was discarded. The G Sepharose was washed 5 x with 1 ml ice-cold wash buffer (50 mM Tris-HCl, pH 8.0, 1% NP-40 and 500 mM NaCl) and bound proteins were eluted by adding 50 μl 2 x SDS/PAGE sample buffer (NuPAGE LDS Sample buffer 4x (Invitrogen), 50 % water added) containing 3.5% ȕ-mercaptoethanol and boiling for 10 min. The eluates were analyzed by SDS/PAGE and Western blotting as described below. Anti-FLAG-Lysates from transiently-transfected HEK293 cells expressing HAI-1-FLAG were generated as above. The EZview Red ANTI-FLAG M2 affinity gel (Sigma) was prepared according to the manufacturers' instructions, and supernatants were pre-cleared with 15 μl affinity gel/sample for 30 min at 4°C with end-over-end rotation. After pre-clearing, the samples were centrifuged at 5000 x g for 1 min at 4°C, and each supernatant was transferred to a new Eppendorf tube containing 50 μl affinity gel. The samples were incubated 1.5 h at 4°C with end-over-end rotation. After incubation, the samples were centrifuged for 30 s at 5000 x g at 4°C to precipitate the affinity gel and the supernatant was discarded. The affinity gel was washed 5 times with 1 ml ice cold wash buffer (50 mM Tris-HCl, pH 8, 1% NP-40 and 500 mM NaCl). The bound proteins were analyzed by Western blotting as described below. Western blotting-Samples were mixed with 4x SDS sample buffer (NuPAGE) containing 7% ȕ-mercaptoethanol and boiled for 10 min, unless otherwise indicated. The proteins were separated on 4-12% Bis-Tris NuPage gels and transferred to 0.2 μm pore size PVDF membranes (Invitrogen). The membranes were blocked with 5% non-fat dry milk in TBS containing 0.05% Tween-20 (TBS-T) for 1 h at RT. The individual PVDF membranes were probed with primary antibodies diluted in 1% non-fat dry milk in TBS-T overnight at 4°C. Antibodies used were sheep anti-human matriptase (AF3946, R&D), mouse anti-human matriptase monoclonal antibody M69 (32), goat anti-human HAI-1 (AF1048, R&D) and mouse anti-human prostasin (BD Transduction Laboratories, Cat# 612173). The next day, the membranes were washed 3 x 5 min in TBS-T, and incubated 1 h with alkaline phosphatase-conjugated secondary antibodies (Thermo Scientific). After 3 x 5 min washes with TBS-T, the signal was developed using nitro blue tetrazolium/5-Bromo-4-chloro-3-indolyl phosphate solution (Pierce, Rockford, IL). PAR-2 activation assay-The assay was performed essentially as described (25) . HEK293 cells (250,000 cells per well) were plated in 24-well poly-L-lysine coated plates and grown for 24 h. Cells were co-transfected with pSRE-firefly luciferase (50 ng) (33), pRL-renilla luciferase (20 ng), pcDNA3.1 containing full-length human protease activated receptor (PAR)-2 cDNA (100 ng) (Missouri S&T cDNA Resource Center, Missouri MO) with different combinations of pcDNA3.1 human matriptase, pcDNA human HAI-1 and pIRES2-EGFP prostasin, as indicated in the individual experiments. The pSRE-firefly luciferase is a luciferase reporter gene under the control of a multimerized serum response element (SRE). The transfection medium was changed after 12 h, and 36 h after transfection, the cells were serum-starved overnight. Cells were lysed and luciferase activity was determined using the dual luciferase assay kit (Promega, Milwaukee, WI) according to the manufacturer's instructions. Luminescence was measured using a Wallac Victor2 1420 Multi-label Counter (Perkin Elmer, Shelton, CT) and the SRE activity was determined as the ratio of firefly luciferase to Renilla luciferase light units. Transgenic mice-All experiments were performed in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited vivarium following Institutional Guidelines and standard operating procedures. Mice expresssing wildtype prostasin under the control of a keratin-5 promotor were generated by cloning an EST that contains the complete full-length 1.02 kb murine prostasin cDNA (I.M.A.G.E. ID 3600399) into the pBK5-vector containing the 5.2 kb bovine keratin-5 regulatory sequences, ȕ-globin intron 2 and 3' polyadenylation sequences (34) . The zymogenlocked and catalytically-inactive prostasin transgenic mice were generated by first introducing either a R44Q point mutation (purchased from Blue Heron) or a S238A point mutation, respectively, in the wildtype prostasin cDNA using the QuickChange Kit (Stratagene); and then cloned into the pBK5-vector. The linearized vectors were fully sequenced and microinjected into the male pro-nucleus of FVB zygotes, which were implanted into pseudopregnant mice. The ensuing founders were genotyped by PCR using the following primer pairs:
and Reverse 5'-ATATATGCGGCCGCTCAAGCCAAAGACAA GAGGCC-3', which amplifies the full-length prostasin cDNA. Histological assessment and immunohistochemical analysis of mouse skin-Dorsal skin samples from 12 to 15 days-old transgenic founders expressing wildtype, zymogen-locked, or catalyticallyinactive prostasin and their non-transgenic littermates were fixed for 24 h in 4 % paraformaldehyde in PBS, embedded into paraffin, sectioned, and stained with hematoxylin and eosin (H&E) prior to histopathological assessment. Immunohistochemical analysis was performed as described previously (35) . Monoclonal anti-human prostasin antibodies (BD Biosciences, San Jose, CA) and rat-anti mouse antibodies against Ki-67 (Dako, Carpinteria, CA, Clone TEC-3) were used for staining. Bound antibodies were visualized with the Vectastain ABC peroxidase kit, as recommended by the manufacturer (Vector Laboratories, Burlingame, CA).
RESULTS
Prostasin stimulates matriptase activation independent of prostasin zymogen conversion or prostasin enzymatic activity-We used a cell-based assay in which wildtype and mutant forms of the two proteases were introduced into HEK293 cells to investigate the mechanistic relationship between matriptase and prostasin. This epithelial cell line expresses low levels of endogenous matriptase and prostasin ( figure 1A and B, lanes 1 and 3 and data not shown) and therefore is well suited to study prostasin-matriptase functional interactions. As described previously, HAI-1 was co-expressed with matriptase and prostasin in all experiments to ensure efficient expression of the two proteases (12, 36) . To eliminate transcriptional effects, empty expression vectors were included in all transfections to ensure that an equal amount of expression plasmid was introduced into each cell. Both matriptase and prostasin were well-expressed in HEK293 cells and could easily be detected in cell lysates and in conditioned medium by Western blot analysis with, respectively, matriptase and prostasin antibodies (figure 1B, lanes 2 and 4). When expressed alone, low levels of activated matriptase were found in cell lysates ( figure Because matriptase is a highly efficient activator of the prostasin zymogen, we hypothesized that prostasin stimulated matriptase activation only after being converted to its active form by low levels of active matriptase generated in HEK293 cells in the absence of prostasin. To challenge this hypothesis, we generated a mutant of prostasin in which arginine 44 was mutated to glutamine, thereby creating a prostasin variant that was refractory to activation by matriptase and other trypsin-like serine proteases. Unexpectedly, however, this "zymogen-locked" prostasin mutant also stimulated matriptase activation (figure 1C, middle panel, compare lanes 1 and 11 with 5-7, and lanes 12 and 22 with [16] [17] [18] . This finding suggested that prostasin either stimulates matriptase activation by a non-proteolytic mechanism or that the prostasin zymogen is endowed with sufficient enzymatic activity to proteolytically activate matriptase. To distinguish between the two possibilities, we next generated a mutant prostasin in which the serine that forms part of the catalytic serine-aspartate-histidine triad (serine 238) was mutated to alanine. Interestingly, this catalytically-inactive prostasin mutant retained its capacity to stimulate matriptase activation in a dose-dependent manner (figure 1C, middle panel compare lanes 1 and 11 with 8-10, and lanes 12 and 22 with 19-21).
Matriptase activation is linked to a rapid formation of inhibitor complexes with HAI-1. These matriptase-HAI-1 complexes subsequently are shed from the cell surface, where they can be detected by non-denaturing SDS/PAGE (reviewed in (37)). We, therefore, next performed nonboiling and non-reducing SDS/PAGE and Western blot analysis of the lysates and culture supernatants of HEK293 cells transfected with matriptase and each of the three prostasin variants as described above. As expected, wildtype prostasin induced the formation of HAI-1-matriptase complexes (figure 1C, bottom panel, compare lanes 1 and 11 with lanes 2-4, and lanes 12 and 22 with 13-15). Consistent with prostasin being capable of stimulating matriptase activation by a non-proteolytic mechanism, both zymogenlocked (figure 1C, bottom panel, compare lanes 1 and 11 with lanes 5-7, and lanes 12 and 22 with 16-18) and catalytically-inactive (figure 1C, bottom panel, compare lanes 1 and 11 with lanes 8-10, and lanes 12 and 22 with 19-21) prostasin also stimulated HAI-1-matriptase complex formation. Taken together, these data demonstrate that catalytically-inactive prostasin is endowed with the capacity to induce the proteolytic conversion of the matriptase zymogen to activated matriptase.
Zymogen-locked and catalytically-inactive prostasin stimulate matriptase-dependent PAR-2 activation-To further investigate the capacity of catalytically-inactive prostasin to stimulate matriptase activation, we used a previously established assay in which the activation of the matriptase target substrate, proteinase activated receptor (PAR)-2, is measured by its ability to induce transcription of a serum response elementluciferase reporter plasmid (25) . PAR-2 is a Gprotein-coupled receptor that is activated by the proteolytic removal of a short N-terminal peptide by trypsin-like serine proteases. Recent studies have shown that prostasin by itself is a poor activator of PAR-2, but that prostasin stimulates PAR-2 activity by converting zymogen matriptase to active matriptase, which then cleaves and activates PAR-2 (25, 28) . In agreement with these previous findings, wildtype prostasin stimulated PAR-2 activation when co-expressed with wildtype matriptase, but not when co-expressed with an inactive matriptase in which serine 805 of the catalytic serine-aspartate-histidine triad was mutated to alanine or when the wildtype prostasin was expressed by itself (figure 2, compare bars 4-6 with bars 2 and 7), confirming that wildtype prostasin stimulates PAR-2 activation through matriptase in this assay. Interestingly, however, both zymogen-locked prostasin and catalyticallyinactive prostasin induced a dose-dependent stimulation of PAR-2 activity in a strictly matriptase-dependent manner, as determined by their ability to increase the activity of PAR-2 when co-expressed with matriptase, but not when expressed in the absence of matriptase (figure 2 compare bars 8-10 with 11, and bars 13-15 with 16), providing further evidence that prostasin can stimulate matriptase activation by a nonproteolytic mechanism.
Zymogen matriptase can activate prostasin-We next investigated the capacity of matriptase to activate prostasin in our reconstituted cell-based assay. Zymogen prostasin and active prostasin are difficult to reliably distinguish by reducing SDS/PAGE, because activation site cleavage and reduction of prostasin leads to the removal of just 12 amino acids, and because prostasin is heterogeneously glycosylated and undergoes C-terminal processing (17) . We, therefore, took advantage of a recently established assay in which activated prostasin is distinguished from zymogen prostasin by its ability to form inhibitor complexes with HAI-1 that can be immunoprecipitated using HAI-1 antibodies, and detected by SDS/PAGE followed by Western blot using prostasin antibodies (25) . As expected, when FLAG-tagged HAI-1 and wildtype prostasin were co-expressed in HEK293 cells in the absence of matriptase, little or no prostasin was immunoprecipitated with antibodies directed against the FLAG-epitope (figure 3, bottom panel, lane 1). As also expected, prostasin was easily coimmunoprecipitated with HAI-1 when the cells coexpressed FLAG-tagged HAI-1, wildtype prostasin, and wildtype matriptase, (figure 3, bottom panel, compare lanes 1 and 2). Interestingly, prostasin could also be coimmunoprecipitated with HAI-1 in cells that coexpressed HAI-1, wildtype prostasin, and several zymogen-locked forms of matriptase, indicating that zymogen matriptase can induce the conversion of zymogen prostasin to active prostasin (figure 3, bottom panel, compare lane 2 with lanes 3-6). Prostasin activation by zymogen matriptase was observed when arginine 614 of matriptase was replaced by alanine, glutamine or glutamic acid or when the entire matriptase propeptide was replaced by the enteropeptidase propeptide ( figure 3, bottom panel, lanes 3-6) . Prostasin mutants with a substitution of the positively charged arginine side-chain with an uncharged glutamine side chain (R614Q, figure 3 , lane 4) or with another positively charged sidechain such as lysine (EP:DDDDK614-VVGG, figure 3 , lane 6), resulted in high levels of prostasin activation. Radical substitutions of the arginine, more likely to alter the conformation of the catalytic site, such as alanine, which has an aliphatic side-chain (R614A, figure 3, lane 3) or glutamate, which has a negatively charged sidechain (R614E, figure 3 , lane 5) gave rise to lower prostasin activation levels. As expected, no activation site cleavage of any of these matriptase mutants was observed, as determined by reducing SDS/PAGE and Western blotting with matriptase antibodies, even when the blot was overexposed (figure 3, upper panel, lanes 3-6 and data not shown). As also predicted, little prostasin coimmunoprecipitated with HAI-1 in cells coexpressing catalytically-inactive matriptase (figure 3, lane 7) or in cells co-expressing zymogenlocked prostasin with wildtype matriptase ( figure  3, lane 8) .
Matriptase and prostasin form protein complexes-The above findings indicated that prostasin can promote matriptase zymogen conversion by a non-canonical mechanism, possibly by serving as a non-enzymatic allosteric co-factor for matriptase autoactivation. To study the potential physical interaction between the two membrane-anchored serine proteases, we next performed a series of co-immunoprecipitation experiments.
Prostasin Matriptase is predominantly located on the basolateral membrane and prostasin, conversely, predominantly is located on the apical membrane in polarized Caco-2 cells. We have previously shown, however, that matriptase and prostasin colocalize for a brief period of time on the basolateral plasma membrane, after which prostasin is transported to the apical membrane as an active protease (31) . To determine if this small fraction of endogenous prostasin that is located on the basolateral membrane of polarized Caco-2 cells forms a complex with matriptase, we performed co-immunoprecipitations of polarized Caco-2 cell lysates using matriptase antibodies. When Caco-2 cells were treated with control shRNA, prostasin could be immunoprecipitated with matriptase antibodies and detected by Western blot (figure 4B, bottom panel, lane 3). As expected from our previous study (31) , only a small fraction of the total Caco-2 cell prostasin coimmunoprecipitated with matriptase (figure 4B, bottom panel, compare lanes 1 and 3). To ensure that this immunoprecipitation of prostasin was specific, Caco-2 cells were treated with matriptase shRNA. This greatly reduced the level of matriptase in these cells (figure 4B, top panel, compare lanes 1 and 2), but did not affect prostasin expression (figure 4B, bottom panel, compare lanes 1 and 2). As expected, little or no prostasin was immunoprecipitated using matriptase antibodies in the matriptase-silenced cells ( figure 4B, bottom panel, lane 4) . Furthermore, no prostasin was immunoprecipitated from lysates of Caco-2 cells treated with control shRNA, when matriptase antibodies were omitted from the procedure ( figure 4B, bottom panel, lane 5) .
Zymogen-locked prostasin, and catalytically-inactive prostasin are biologically active in vivo-A recent study reported that epidermal overexpression of wildtype prostasin in transgenic mice causes severe epidermal thickening and scaling (ichthyosis), skin inflammation, and ulceration (38) . We used this observation as a convenient tool to establish if zymogen-locked and catalytically-inactive prostasin displayed biological activity in an in vivo setting, as would be predicted from the above studies. Specifically, we generated transgenic mice expressing wildtype, zymogen-locked, and catalytically-inactive prostasin under the control of a keratin-5 promoter. In agreement with the abovecited study, epidermal overexpression of wildtype prostasin resulted in a severe skin phenotype. This phenotype, which manifested within the first week of life, was observed in 9 out of 15 (60%) of transgenic founders (table 1, representative examples in figure 5A ). Due to the severity of the phenotype, the pre-weaning survival and the fertility of the founders were low (table 1 and data not shown). Histological examination of moribund founders revealed severe ichthyosis, with epidermal hyperproliferation and hyperkeratosis (figure 5, compare panel D with G, panel E with H, and panel F with I), thus, replicating the above cited study (38) . Interestingly, however, epidermal overexpression of either zymogen-locked or catalytically-inactive prostasin resulted in transgene founder phenotypes that were indistinguishable in outward (figure 5, compare panels B and C with A) and histological (figure 5, compare panels J and M with G, panels K and N with H, and panels L and O with I) appearance from mice expressing wildtype prostasin. Thus, a severe skin phenotype was observed in 6 of 8 (75 %) of transgenic founders expressing either zymogen-locked or catalytically-inactive prostasin, resulting in poor pre-weaning survival and fertility of the founders (table 2 and 3, and data not shown). No phenotype was observed in eight of eight transgenic founders injected with the empty transgene vector (data not shown). Taken together, this shows that zymogen-locked prostasin and catalytically-inactive prostasin are endowed with biological activity in vivo, and that they can elicit phenotypes that are identical to those elicited by wildtype prostasin when overexpressed in mouse epidermis.
DISCUSSION
A wealth of data now firmly establishes matriptase and prostasin as part of a single cell surface proteolytic pathway crucial for regulating epithelial development and maintaining epithelial homeostasis (reviewed in (7)). Conflicting data have emerged, however, regarding the hierarchical placement and functional interrelationship of the two proteases in this pathway, with biochemical and genetic data placing prostasin as either upstream or downstream from matriptase, depending on the specific context. In this paper, we present biochemical and genetic data that may reconcile some of these conflicting data. Thus, we show that matriptase and prostasin form a reciprocal zymogen activation complex, and that the engagement of the two protease zymogens can result in the formation of both active matriptase and active prostasin. Surprisingly, the ability of prostasin to induce matriptase activation can occur independently of prostasin undergoing activation site cleavage or even of the catalytic activity of prostasin, as shown by the ability of both zymogen-locked and catalytically-inactive prostasin to stimulate matriptase zymogen conversion. We speculate that prostasin may do so by inducing a conformational change in the serine protease domain of matriptase that favors matriptase auto-activation, by displacing an inhibitory matriptase stem domain, or by attracting or displacing as yet unidentified ternary factors. Elucidation of these outstanding questions would be greatly stimulated by solving the structure of the intact matriptase ectodomain or even the intact matriptase ectodomain complexed with prostasin.
The reduced complex formation of prostasin with zymogen-locked matriptase and catalytically-inactive matriptase, as compared to wildtype matriptase, tentatively suggests that prostasin forms exosite interactions with the matriptase serine protease domain. Alternatively, activated matriptase may promote complex formation with prostasin by cleaving or removing one of its domains or an unknown ternary protein.
In this regard, it is interesting to note that the soluble activated ectodomain of matriptase has been shown to cleave its second CUB domain (39) . Furthermore, although both zymogen-locked and catalytically-inactive prostasin stimulated matriptase zymogen conversion, they did so less efficiently than wildtype prostasin. It is, therefore, entirely conceivable that prostasin, once activated by matriptase, also promotes matriptase zymogen conversion by direct proteolytic cleavage of the matriptase activation site. Compatible with this notion, we found that wildtype prostasin stimulated the activation site cleavage of catalytically-inactive matriptase, when the two proteases were co-expressed in HEK293 cells (figure 3, upper panel, lane 7 and data not shown). The latter finding is at odds with a recent study reporting that purified prostasin is incapable of activating the purified soluble matriptase zymogen even at very high concentrations in vitro (29) . This leaves open the possibility that prostasin stimulates matriptase activation entirely by nonproteolytic means, and that activated prostasin, thus, must adopt a conformation more favorable for inducing matriptase auto-activation or for recruiting a hypothetical ternary matriptaseactivating protease than do zymogen-locked prostasin and catalytically-inactive prostasin. It is important to note, however, that the matriptase used in the cited study lacked the entire stem region, which may provide critical exosite interactions stimulating prostasin catalytic activity towards matriptase, and that the recombinant matriptase and prostasin used in the study also lacked membrane-anchorage. It is, therefore, still quite plausible that prostasin, once activated by matriptase or by a hypothetical ternary protease, proteolytically converts zymogen matriptase to active matriptase, thereby accelerating reciprocal zymogen activation analogous to the cell surface urokinase plasminogen activation cascade (40, 41) .
In support of the observations discussed above, we found that epidermal overexpression of either zymogen-locked prostasin or catalyticallyinactive prostasin induced a skin phenotype in transgenic mice that was indistinguishable from the phenotype observed by epidermal overexpression of wildtype prostasin by us and by others (38) . The severity of this phenotype was largely incompatible with pre-weaning survival and the fertility of transgenic founders, thus limiting detailed phenotypic analysis. Nevertheless, the data underscore that zymogenlocked prostasin and catalytically-inactive prostasin are indeed biologically active in vivo.
An additional novel finding in our study is that the zymogen form of matriptase was an efficient activator of prostasin, as based on the capacity of several zymogen-locked versions of matriptase to efficiently stimulate prostasin zymogen conversion. This finding is entirely consistent with previous published studies showing that the matriptase zymogen has a low, but detectable, activity towards small model substrates (14) . It remains to be established if zymogen matriptase can also cleave other matriptase target substrates. If the latter is the case, it raises the interesting possibility that prostasinmediated matriptase zymogen conversion can function as an "off-switch" for some matriptasedependent proteolytic processes, because activated matriptase, but not zymogen matriptase, is susceptible to rapid inactivation by Kunitz-and serpin-type serine protease inhibitors.
The reciprocal zymogen activation model proposed in the current study provides a plausible mechanism for the activation of matriptase in the context of development and homeostasis of some polarized epithelia, as well as in some pathological conditions, such as breast cancer, where the twoproteases are near-ubiquitously co-expressed (42) . It is important to underscore, however, that additional mechanisms for matriptase activation quite certainly exist. For example, matriptase is expressed and active on subsets of human hematopoietic cells that have not been reported to express prostasin (15, 43, 44) .
Importantly, our finding that prostasin can serve as a non-proteolytic co-factor for activation of a heterologous trypsin-like serine protease may also explain previous perplexing data regarding the proteolytic activation of the epithelial sodium channel (ENaC) by prostasin. ENaC is a heterotetramer composed of homologous D, E, and J subunits that combine to form a sodium-selective channel (45) (46) (47) . The activity of the channel is greatly increased by proteolytic cleavage of the ENaC J subunit after the sequence RKRK 186 (48-51). Several membrane-anchored serine proteases, including TMPRSS3, TMPRSS4, matriptase, and prostasin all can activate ENaC (52-54). Prostasin, however, is unique in this regard, in that catalytically-inactive prostasin induces efficient ENaC J chain cleavage and activation, which can be blocked by aprotinin and requires an intact RKRK 186 J chain sequence (48, 55) . This finding, which has been independently reproduced in two laboratories, lends further support to our proposed model of prostasin functioning at least in part as a non-enzymatic co-factor for zymogen conversion of other serine proteases.
In summary, the current study has provided biochemical and genetic evidence for the existence of a matriptase-prostasin reciprocal zymogen activation complex. Unique features of this activation complex include the ability of prostasin to serve as non-enzymatic co-factor for matriptase zymogen activation and the capacity of zymogen matriptase to proteolytically activate prostasin.
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